Among the very tight Republican and Democrat contests anticipated in this November’s US midterm elections are more than a few device industry-favored candidates, according to a review of the incumbents’ voting records and recent polling data.
Many US politicians who have a history of supporting the medtech industry are finding themselves in close political races this fall, as they vie to retain old seats, or reach up to capture new ones.
In fact, for at least four candidates who have backed device-favorable legislation in the past several years, their competitions against challengers are considered toss-ups, according to polling groups and analysts,...
During MD&M East last week, regulatory consultant Darren Reeves reminded device manufacturers that the time to get ready to comply with the new Quality Management System Regulation is now.
Speakers at a recent UK medtech outlook conference voiced optimism about the sector’s prospects, but warned that cost burdens, over-regulation and lengthy processes will impede the capacity of local SMEs to innovate. Only 10% of NHS procured medtech comes from UK manufacturers.
The FDA plans to announce class II status for four new device types, including tests for the Zika virus and genetic condition Fragile X. This follows earlier announcements and highlights a trend toward diagnostic classifications. The classifications are considered deregulatory, meaning they will hel
